It was used to perform neurolept anaesthesia in combination with fentanyl until a Food and Drug Administration (FDA) 'black box' warning restricted its use due to cardiovascular side effects in 2001.
Neurolept anaesthesia was one of the regimens used, which combined droperidol, a butyrophenone acting by blocking D2 receptors, and fentanyl, an opioid.
Saeki et al reported the successful use of this strategy in a patient with neurolept malignant syndrome requiring electroconvulsive therapy (3).
Electroconvulsive therapy using rocuronium and sugammadex in a patient with neurolept malignant syndrome.
Transcutaneous cranial electrical stimulation decreases narcotic requirements during neurolept
anesthesia and operation in man.